Baseline characteristics of iMCD patients treated with the TCP regimen (n = 25)
| Characteristics . | Normal range . | All patients, n = 25 . | Responders, n = 12 . | Nonresponders, n = 13 . | P . |
|---|---|---|---|---|---|
| Age, median (range), y | 40 (20-63) | 38 (20-63) | 41 (29-61) | .660 | |
| Sex, male, n (%) | 17 (68) | 9 (75) | 8 (61.5) | .574 | |
| Histology | .152 | ||||
| Hyaline vascular | 10 (40%) | 6 | 4 | ||
| Plasmacytic | 11 (44%) | 6 | 5 | ||
| Mixed | 4 (16%) | 0 | 4 | ||
| ECOG-PS | .852 | ||||
| 0 | 11 (44%) | 6 | 5 | ||
| 1 | 11 (44%) | 4 | 7 | ||
| 2 | 3 (12%) | 2 | 1 | ||
| Symptom score, median (range) | 14 (6-41) | 16 (7-38) | 13 (6-41) | .666 | |
| Fever, n (%) | 14 (56) | 10 (83.3) | 4 (30.8) | .008 | |
| Weight loss, n (%) | 19 (76) | 10 (83.3) | 9 (69.2) | .645 | |
| Peripheral lymphadenopathy, n (%) | 23 (92) | 12 (100) | 11 (84.6) | .480 | |
| Splenomegaly, n (%) | 9 (36) | 3 (25) | 6 (46.2) | .411 | |
| Skin involvement,* n (%) | 8 (32) | 3 (25) | 5 (38.5) | .673 | |
| Pulmonary involvement, n (%) | 5 (20) | 0 (0) | 5 (38.5) | .039 | |
| Anasarca, n (%) | 6 (24) | 3 (25) | 3 (23.1) | 1.000 | |
| IL-6, median (range), pg/mL | <5.9 | 21.3 (7.4-865) | 28.55 (7.4-865) | 20.7 (7.7-61.9) | .437 |
| Hemoglobin, median (range), g/L | Male, 120-160; female, 110-150 | 100 (73-141) | 98 (76-133) | 102.5 (73-141) | .931 |
| Platelet count, median (range), 109/L | 100-350 | 297 (64-725) | 167 (64-688) | 322.5 (64-725) | .689 |
| Serum creatinine, median (range), μmol/L | Male, 59-104; female, 45-84 | 55 (25-182) | 55 (42-182) | 58.5 (25-138) | .782 |
| CRP, median (range), mg/L | 0-8 | 73.9 (0.2-185.6) | 41.625 (0.2-185.6) | 85.685 (1.6-119.2) | .453 |
| ESR, median (range), mm/h | Male, 0-15; female, 0-20 | 97.5 (2-140) | 90 (6-115) | 102 (2-140) | .178 |
| Albumin, median (range), g/L | 35-52 | 32 (24-43) | 32 (26-43) | 31 (24-43) | .623 |
| IgG, median (range), g/L | 7.00-17.00 | 25.9 (5.3-85.1) | 21.74 (14.4-43.8) | 36.475 (5.3-85.1) | .221 |
| Characteristics . | Normal range . | All patients, n = 25 . | Responders, n = 12 . | Nonresponders, n = 13 . | P . |
|---|---|---|---|---|---|
| Age, median (range), y | 40 (20-63) | 38 (20-63) | 41 (29-61) | .660 | |
| Sex, male, n (%) | 17 (68) | 9 (75) | 8 (61.5) | .574 | |
| Histology | .152 | ||||
| Hyaline vascular | 10 (40%) | 6 | 4 | ||
| Plasmacytic | 11 (44%) | 6 | 5 | ||
| Mixed | 4 (16%) | 0 | 4 | ||
| ECOG-PS | .852 | ||||
| 0 | 11 (44%) | 6 | 5 | ||
| 1 | 11 (44%) | 4 | 7 | ||
| 2 | 3 (12%) | 2 | 1 | ||
| Symptom score, median (range) | 14 (6-41) | 16 (7-38) | 13 (6-41) | .666 | |
| Fever, n (%) | 14 (56) | 10 (83.3) | 4 (30.8) | .008 | |
| Weight loss, n (%) | 19 (76) | 10 (83.3) | 9 (69.2) | .645 | |
| Peripheral lymphadenopathy, n (%) | 23 (92) | 12 (100) | 11 (84.6) | .480 | |
| Splenomegaly, n (%) | 9 (36) | 3 (25) | 6 (46.2) | .411 | |
| Skin involvement,* n (%) | 8 (32) | 3 (25) | 5 (38.5) | .673 | |
| Pulmonary involvement, n (%) | 5 (20) | 0 (0) | 5 (38.5) | .039 | |
| Anasarca, n (%) | 6 (24) | 3 (25) | 3 (23.1) | 1.000 | |
| IL-6, median (range), pg/mL | <5.9 | 21.3 (7.4-865) | 28.55 (7.4-865) | 20.7 (7.7-61.9) | .437 |
| Hemoglobin, median (range), g/L | Male, 120-160; female, 110-150 | 100 (73-141) | 98 (76-133) | 102.5 (73-141) | .931 |
| Platelet count, median (range), 109/L | 100-350 | 297 (64-725) | 167 (64-688) | 322.5 (64-725) | .689 |
| Serum creatinine, median (range), μmol/L | Male, 59-104; female, 45-84 | 55 (25-182) | 55 (42-182) | 58.5 (25-138) | .782 |
| CRP, median (range), mg/L | 0-8 | 73.9 (0.2-185.6) | 41.625 (0.2-185.6) | 85.685 (1.6-119.2) | .453 |
| ESR, median (range), mm/h | Male, 0-15; female, 0-20 | 97.5 (2-140) | 90 (6-115) | 102 (2-140) | .178 |
| Albumin, median (range), g/L | 35-52 | 32 (24-43) | 32 (26-43) | 31 (24-43) | .623 |
| IgG, median (range), g/L | 7.00-17.00 | 25.9 (5.3-85.1) | 21.74 (14.4-43.8) | 36.475 (5.3-85.1) | .221 |
P values shown in bold represent statistically significant (P < .05) differences between responders and nonresponders.
One patient had pemphigus.